* Standard BioTools Inc LAB.OQ reported a quarterly
adjusted
loss of 7 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -27 cents. The mean expectation of
three analysts for the quarter was for a loss of 9 cents per
share. Wall Street expected results to range from -10 cents
to -8 cents per share.
* Revenue rose 77.3% to $44.97 million from a year ago;
analysts
expected $41.00 million.
* Standard BioTools Inc's reported EPS for the quarter was a
loss
of 7 cents.
* The company reported a quarterly loss of $26.94 million.
* Standard BioTools Inc shares had fallen by 9.3% this
quarter and
lost 20.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Standard BioTools
Inc is 2.75
This summary was machine generated from LSEG data October 31 at
02:36 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.09 -0.07 Beat
Jun. 30 2024 -0.08 -0.12 Missed
Mar. 31 2024 -0.11 -0.27 Missed
Dec. 31 2023 -0.13 -0.25 Missed